Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22729424 | 0.77 | POLB (0.41) | BRD4 | |
| SCHEMBL22729485 | 0.73 | BRD4 (0.39) | BRD4 | |
| SCHEMBL22729430 | 0.72 | BRD4 (0.31) | BRD4 | |
| SCHEMBL24322356 | 0.62 | PDPK1 (0.36) | — | |
| Hydrochloric Acid SCHEMBL22729563 | 0.61 | KDM4E (0.36) | BRD4 | |
| SCHEMBL23201571 | 0.60 | BRD4 (0.41) | BRD4 | |
| SCHEMBL16060757 | 0.59 | BRD4 (0.50) | BRD4 | |
| SCHEMBL19533290 | 0.59 | CDK8 (0.34) | — | |
| SCHEMBL22306200 | 0.59 | F2RL3 (0.39) | BRD4PARP1 | |
| SCHEMBL147830 | 0.58 | BRD4 (0.51) | BRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11459325-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2022-10-04 | — | — | US | disclosed |
| US-20210087186-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2021-03-25 | — | — | US | disclosed |
| EP-3747885-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2020-12-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210087186-A1 | HETEROCYCLIC COMPOUND | GBA1, GBA2, GALC | BRD4 1170/4885PARP1 3178/4885 |
| US-11459325-B2 | Heterocyclic compound | GBA1, GBA2, GALC | BRD4 1201/4885PARP1 3056/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.